Tenecteplase：血栓溶解劑的新希望？

For intravenous thrombolysis of acute ischemic stroke, recombinant tissue plasminogen activator (rt-PA) remains the evidence-based and regulatory-approved choice worldwide. However, tenecteplase (TNK) is a genetically modified version of rt-PA and equipped with more favorable pharmacodynamic and pharmacokinetic properties over rt-PA. Stroke neurologists are keen to know whether this newer agent could be successfully applied, or even replaced, rt-PA, in the field of acute ischemic stroke. In this review, I will briefly review the up-to-date evidences on the efficacy and safety of TNK in acute stroke, with special focusing on the completed and ongoing randomized clinical trials comparing TNK to rt-PA. The pros and cons of TNK compared to rt-PA in clinical practice will also be scrutinized. Overall, TNK remains the most alluring option and potent competitor in the field of thrombolysis.

並列關鍵字

acute ischemic stroke ； alteplase ； tenecteplase ； thrombolysis

國際替代計量

全文下載

主題瀏覽